Comparative Pharmacology
Head-to-head clinical analysis: DILTIAZEM HYDROCHLORIDE IN 0 72 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILTIAZEM HYDROCHLORIDE IN 0 72 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderate3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."